EQRx, Inc.
http://www.eqrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EQRx, Inc.
Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.
Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
2021 Venture Investment Was Bullish – Will 2022 Be The Same?
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
The IPO Party Is Over – How Bad Is The Hangover?
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals